Total number of patients with Crohn’s disease of ulcerative colitis to receive biologic treatments (infliximab, adalumimab) between 2016 and 2020 inclusive who were 1. White New Zealander 2. Maori 3 Asian (Ideally separated into South Asian and East Asian) 5. Pacific Islanders by each ethnicity separately